(Q34799386)

English

Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

0 references

1 reference

Europe PubMed Central

Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

R San Miguel

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

F Guillén

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

J M Cabasés

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

M Buti

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1611-1621

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Nonresponse to interferon in chronic hepatitis C: re-treatment redux.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Quality of reporting of meta-analyses: the QUOROM statement. Will it help?

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: a preliminary study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, Franc

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon-alpha in interferon nonresponders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon plus ribavirin in chronic hepatitis C non-responders to recombinant alpha-interferon.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Quality assessment of reports on clinical trials in the Journal of Hepatology

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01328.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2002.01328.X

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34799386&oldid=1959153389"